Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4326MR)

This product GTTS-WQ4326MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4326MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8538MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ9368MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ3426MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ6807MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ2641MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ8594MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ5904MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ14679MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW